{
    "clinical_study": {
        "@rank": "10092", 
        "arm_group": [
            {
                "arm_group_label": "Vaccine + Placebo at 1.0 mg", 
                "arm_group_type": "Experimental", 
                "description": "1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid\u2122 Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28."
            }, 
            {
                "arm_group_label": "Vaccine at 1.0 mg", 
                "arm_group_type": "Experimental", 
                "description": "1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid\u2122 Delivery System (TDS) on Study Day 0, 28, 56 and 168."
            }, 
            {
                "arm_group_label": "Vaccine + Placebo at 2.0 mg", 
                "arm_group_type": "Experimental", 
                "description": "2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid\u2122 Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28."
            }, 
            {
                "arm_group_label": "Vaccine at 2.0 mg", 
                "arm_group_type": "Experimental", 
                "description": "2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid\u2122 Delivery System (TDS) on Study Day 0, 28, 56 and 168."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the immune responses of two different doses (1.0 mg\n      and 2.0 mg) and two different dosing schedules (two doses or three doses) of a mixed Hantaan\n      virus (HTNV) and Puumala virus (PUUV) DNA vaccine in healthy participants. To maintain a\n      blind, participants in the two-dose group will receive one dose of normal saline placebo.\n      All of the groups will also receive a booster dose 6 months after first vaccination. The\n      results will help to determine which dose and vaccination schedule will be best to move\n      forward in the vaccine development process."
        }, 
        "brief_title": "Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemorrhagic Fever With Renal Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Fever", 
                "Hemorrhagic Fever with Renal Syndrome", 
                "Hemorrhagic Fevers, Viral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult male or non-pregnant, non-lactating female, ages 18-49 (inclusive) at\n             the time of screening\n\n          -  Have provided written informed consent before screening\n\n          -  Free of clinically significant health problems, as determined by pertinent medical\n             history and clinical examination prior to entry into the study\n\n          -  Available and able to participate for all study visits and procedures\n\n          -  Females, if sexually active, are known to be at least one year post-menopausal\n             (defined as no menses for 12 consecutive months), or willing to use an effective\n             method of contraception (eg, hormonal contraception, diaphragm, cervical cap,\n             intrauterine device, condom, anatomical sterility [self or partner]) from the date of\n             screening until at least 3 months after the last injection\n\n          -  Negative hantavirus pseudovirion neutralization assay (PsVNA) test result at\n             screening\n\n        Exclusion Criteria:\n\n          -  History or serologic evidence of prior infection with any hantavirus virus, or prior\n             participation in a HTNV or PUUV vaccine trial\n\n          -  History of severe local or systemic reactions to any vaccination or a history of\n             severe allergic reactions\n\n          -  Ongoing participation in another clinical trial\n\n          -  Receipt or planned receipt of any vaccination, experimental or otherwise within the\n             period 30 days prior to the first injection through the period 60 days after Study\n             Day 168 (booster dose; approximately 9 month period in total), with the exception of\n             emergency use vaccinations as needed\n\n          -  Individuals in whom a skinfold measurement of the cutaneous and subcutaneous tissue\n             for all eligible injection sites (deltoid region) exceeds 40 mm\n\n          -  Individuals in whom the ability to observe possible local reactions at the eligible\n             injections sites (deltoid region) is, in the opinion of the investigator,\n             unacceptably obscured due to a physical condition or permanent body art\n\n          -  Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or\n             hepatic or renal functional abnormality as determined by the investigator based on\n             medical history, physical exam, electrocardiogram (ECG), and/or laboratory screening\n             test\n\n          -  Pregnant or lactating female, or female who intends to become pregnant during the\n             study period\n\n          -  Administration of immunoglobulins and/or any blood products within the 120 days\n             preceding study entry or planned administration during the study period\n\n          -  Any serologic evidence of hepatitis B or C infection\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including\n             human immunodeficiency virus (HIV) infection\n\n          -  Administration of chronic (defined as more than 14 days) immunosuppressants or other\n             immune modifying drugs within 6 months of study entry\n\n               1. For corticosteroids, this will mean prednisone, or equivalent, greater than or\n                  equal to 0.5 mg/kg/day\n\n               2. Intranasal and topical steroids are allowed\n\n          -  Any chronic or active neurologic disorder, including seizures and epilepsy, excluding\n             a single febrile seizure as a child\n\n          -  Syncopal episode within 12 months of screening\n\n          -  Suspected or known current alcohol and/or illicit drug abuse\n\n          -  Unwilling to allow storage and use of blood for future hantavirus-related research\n\n          -  Any other significant finding that in the opinion of the investigator would increase\n             the risk of the individual having an adverse outcome from participating in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116205", 
            "org_study_id": "S-14-01", 
            "secondary_id": "2085"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Vaccine + Placebo at 1.0 mg", 
                    "Vaccine at 1.0 mg", 
                    "Vaccine + Placebo at 2.0 mg", 
                    "Vaccine at 2.0 mg"
                ], 
                "description": "HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)", 
                "intervention_name": "HTNV/PUUV DNA vaccine", 
                "intervention_type": "Biological", 
                "other_name": "Hantaan Virus/Puumala Virus DNA Vaccine"
            }, 
            {
                "arm_group_label": [
                    "Vaccine + Placebo at 1.0 mg", 
                    "Vaccine + Placebo at 2.0 mg"
                ], 
                "description": "0.9% sodium chloride", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological", 
                "other_name": "Normal saline placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hantaan virus", 
            "Puumala virus", 
            "HFRS"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "contact": {
                "email": "kristopher.m.paolino.mil@mail.mil", 
                "last_name": "Kristopher M Paolino, MD", 
                "phone": "301-319-9072"
            }, 
            "facility": {
                "address": {
                    "city": "Silver Spring", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20910"
                }, 
                "name": "Walter Reed Army Institute of Research Clinical Trials Center"
            }, 
            "investigator": {
                "last_name": "Kristopher M Paolino, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device for Prevention of Hemorrhagic Fever With Renal Syndrome", 
        "overall_contact": {
            "email": "kristopher.m.paolino.mil@mail.mil", 
            "last_name": "Kristopher Paolino, MD", 
            "phone": "301-319-9072"
        }, 
        "overall_official": {
            "affiliation": "WRAIR Clinical Trials Center", 
            "last_name": "Kristopher Paolino, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint will be to determine the seroconversion rates of the vaccines. Seroconversion is defined as production of neutralizing antibody titers measured using a pseudovirion neutralization assay (PsVNA). A PsVNA50 titer \u2265 20 is considered positive.", 
            "measure": "Seroconversion rates of the HTNV/PUUV DNA vaccine", 
            "safety_issue": "No", 
            "time_frame": "Study Days 0 to 365"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Solicited AEs occurring from the time of each injection through 14 days following the procedure, with the first 7 days following vaccination to be assisted with a memory aid.", 
            "measure": "Rate of adverse events (AEs) in study subjects", 
            "safety_issue": "Yes", 
            "time_frame": "Study Days 0 to 14, 28 to 42, 56 to 70 and 168 to 182"
        }, 
        "source": "U.S. Army Medical Research and Materiel Command", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Walter Reed Army Institute of Research (WRAIR)", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "Ichor Medical Systems Incorporated", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "United States Army Medical Materiel Development Activity", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "United States Army Medical Research Institute of Infectious Diseases", 
                    "agency_class": "U.S. Fed"
                }
            ], 
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}